课题基金 / 基金详情

项目摘要

项目成果

XIAO-Ou SHU的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):在中国,随着经济的快速发展、现代化和西式生活方式的采用,慢性病的流行也随之出现。因此,在中国的大多数城市,心血管疾病和癌症现在已经取代传染病成为首要死亡原因。随着中国人口老龄化,慢性病的负担预计将继续增加。范德比尔特医学与公共卫生研究所和范德比尔特全球卫生研究所正在与上海预防医学研究院(SIPM)、复旦大学和上海肿瘤研究所(SCI)合作,建立范德比尔特-上海慢性病研究培训项目(VU-Shanghai CDRTP)。CDRTP的具体目标是:(1)培养一支进行多学科慢性病研究的专家干部队伍,建设中国的培训能力;(2)培养专家干部队伍,开展多学科慢性病研究,建设培训能力;(3)建设中国的研究能力,并与范德比尔特慢性病研究人员建立长期的合作关系;(4)确保并记录中国通过该奖项正在推动和升级的培训项目的长期成功;(5)通过现有的和新建立的网络,在慢性病预防和控制领域建立国内和国际领先的地位。培训计划包括学者培训(范德比尔特大学3个月)、研究生培训(复旦大学1-2年教学课程工作、SIPM或SCI为期3个月的研究实习、范德比尔特大学1年的论文研究)、两个为期5天的国内研讨会和一个国际会议。培训将侧重于先进的流行病学和生物统计学方法,设计和执行多学科研究项目,培养癌症、心血管疾病和糖尿病研究方面的专门知识,以及编写赠款的技能。VU-Shanghai CDRTP建立在现有研究和培训计划的基础上,以及参与机构之间的长期合作,将对中国的慢性病研究和预防产生重大和长期的影响。公共卫生相关性:慢性病正在成为中国的主要健康负担。范德比尔特将与上海的公共卫生领导人合作,培训慢性病研究方面的专家干部和下一代研究人员,建设研究能力和当地培训设施。该项目将对中国的慢性病研究和预防产生重大影响,并可能推广到其他发展中国家。
英文摘要
DESCRIPTION (provided by applicant): The rapid economic development, modernization and adoption of a Western lifestyle in China have been accompanied by the emergence of chronic disease epidemics. As a result, cardiovascular disease and cancer have now replaced infectious diseases as the leading causes of death in most cities in China. The burden of chronic disease is expected to continue increasing as the Chinese population ages. The Vanderbilt Institute for Medicine and Public Health and the Vanderbilt Institute for Global Health are partnering with the Shanghai Institutes of Preventive Medicine (SIPM), Fudan University, and the Shanghai Cancer Institute (SCI) to establish the Vanderbilt-Shanghai Chronic Disease Research Training Program (VU-Shanghai CDRTP). The specific aims of the CDRTP are: (1) to train a cadre of experts to conduct multi-disciplinary chronic disease research and build training capacity in China; (2). to train a new generation of scientists and future leaders in chronic diseases research in China; (3) to build research capacity in China and establish long-term collaborative relationships with Vanderbilt chronic disease researchers; (4) to ensure and document the long-term success of the training programs in China that are being facilitated and upgraded through this award; (5) to build national and international leadership in chronic disease prevention and control through existing and newly established networks. The training program includes scholar training (3 months at Vanderbilt), graduate training (1-2 years of didactic course work at Fudan University, a 3-month research practicum at SIPM or SCI, and 1 year of thesis research at Vanderbilt), two five-day, in-country workshops, and an international conference. The training will focus on advanced epidemiological and biostatistical methodology, design and execution of multidisciplinary research projects, and building expertise on cancer, cardiovascular disease and diabetes research, as well as grant writing skills. The VU-Shanghai CDRTP, building upon the strength of existing research and training programs and long-standing collaborations among the participating institutes, will have a significant and long-term impact on chronic disease research and prevention in China. PUBLIC HEALTH RELEVANCE: Chronic disease is emerging as the leading health burden in China. Vanderbilt will partner with public health leaders in Shanghai to train cadre of experts and next generation of researchers in chronic disease research, to build the research capacity and local training facilities. This program will have significant impact on chronic disease research and prevention in China, and possibly extend to other developing countries.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Vanderbilt Training Program in Molecular and Genetic Epidemiology of Cancer
Vanderbilt Training Program in Molecular and Genetic Epidemiology of Cancer
Vanderbilt Training Program in Molecular and Genetic Epidemiology of Cancer
Regional Center of Research Excellence in Cancer and Other Non-Communicable Disease Epidemiology and Prevention in Vietnam
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: